Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus ZMAX.
ERYTHROCIN STEARATE vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic